MatrileX Laboratories is pleased to highlight the publication of a new peer-reviewed study, “Induction of proximal tubular proliferation and lengthening in response to sodium–glucose cotransporter-2 inhibition in experimental rats.” This work provides mechanistic insight into why SGLT2 inhibitors reduce renal glucose reabsorption by only ~50%, despite SGLT2 handling >90% of filtered glucose under normal physiology.
Summary of Findings
Using stereological methods to distinguish cortical S1/S2 (SGLT2-rich) from outer medullary S3 (SGLT1-rich) proximal tubules, the study demonstrates a clear compensatory remodeling response to SGLT2 inhibition:
- Early hyperplasia in S3 segment
Dapagliflozin induced a three-fold increase in Ki67-positive proliferating cells (P < 0.0001). - Subsequent structural expansion
The S3 segment underwent a 32% increase in tubular length (P < 0.0001). - No change in S1/S2 length
The predominantly SGLT2-expressing cortical segments remained structurally unchanged.
Implications
These findings support a physiological adaptation in which SGLT1-expressing S3 tubules expand to reclaim more glucose, limiting glucosuria and helping explain the smaller-than-expected reduction in glucose reabsorption during SGLT2 inhibition. This mechanistic framework has important implications for interpreting drug efficacy, compensatory renal responses, and combination therapeutic strategies.
Full publication: https://doi.org/10.1111/jdi.70043
